Please don't take your organs to heaven,heaven knows we need them here
Followers | 517 |
Posts | 102,285 |
Boards Moderated | 2 |
Alias Born | 01/18/2003 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
weird on the race today with 19 to go 2nd stage all drivers locked..cwazy race indeed..
Nice move today wakey wakey...cmon audit time name change ticker...LFG
NEWS: LPTV:
Loop Media Launches Exclusive Sports News Highlights Channel and Proprietary SportsLoop Ticker
April 14 2023 - 09:09AM
Business Wire
Print
Share On Facebook
The Channel and Ticker Establish Loop TV’s Leadership Position in Major Sports Highlights and Information
Loop Media, Inc. (“Loop Media” or “Loop”) (NYSE American: LPTV), a leading multichannel streaming platform that provides curated music video, sports, news and entertainment channels for businesses, today announced the launch of a new Sports News Highlights channel featuring 24/7 sports highlights and headlines from the major leagues and sporting events worldwide. The channel is available exclusively on Loop-enabled digital-out-of-home (“DOOH”) venues through Loop’s proprietary Loop Player for businesses.
The Sports News Highlights channel will provide viewers with up-to-date scores from major sporting events including the NFL, NBA, MLB, NHL, PGA, MLS as well as college sports, motor sports, tennis, and more. Launching alongside the channel is the SportsLoop ticker, a proprietary widget that businesses can use to turn any Loop TV channel into a sports channel. The SportsLoop ticker will provide real time news, scores and schedules for all major league and college sports.
“Sports channels connect fans to their favorite teams and to one another,” said Bob Gruters, Chief Revenue Officer for Loop Media. “With Loop’s exclusive Sports News Highlights channel and 24/7 SportsLoop ticker, sports fans never miss a moment of the action. Fans will love watching, businesses will love hosting, and advertisers will love streaming – everybody wins.”
Sports News Highlights is provided by Bridge Media Networks, and the data for SportsLoop ticker is provided by Stats Perform, the leader in sports data and predictive analytics.
About Loop Media, Inc.
Loop Media, Inc. (“Loop Media”) (NYSE American: LPTV) is a leading digital out of home (DOOH) TV and digital signage platform optimized for businesses, streaming more than 200 free music video, news, sports and entertainment channels through its Loop TV service. Loop Media is the leading company in the U.S. licensed to stream music videos to businesses through its proprietary Loop Player.
Loop Media’s digital video content reaches millions of viewers in DOOH locations including bars/restaurants, office buildings, retail businesses, college campuses, airports and on free ad-supported TV platforms like Roku and at local gas stations on GSTV terminals and in 400,000 hotel rooms in over 1300 hotels in the United States.
Loop is fueled by one of the largest and most important video libraries that includes music videos, movie trailers and live performances. Loop Media’s non-music channels cover a multitude of genres and moods and include movie trailers, sports highlights, lifestyle and travel videos, viral videos and more. Loop Media’s streaming services generate revenue from advertising, sponsorships, integrated marketing and branded content, and from subscriptions.
To learn more about Loop Media products and applications, please visit us online at Loop.tv
Follow us on social:
Instagram: @loopforbusiness
Twitter: @loopforbusiness
LinkedIn: https://www.linkedin.com/company/loopforbusiness
Mornin All~~!!
Audit ticker change symbol change and buckle up folks..cant be far off..
BWVI NEWS:Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
PR Newswire
10:00 AM ET
As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect™ketamine topical to treat PTSD, the company is named to Life Science Review's yearly Top Biotech Start-Up List
Psycheceutical Bioscience, Inc("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review'sTop 10 Biotech Startups for 2023. Psycheceutical earned recognition for its significant progress in developing innovative patented delivery technologies that are intended to increase the safety and efficacy of psychedelic compounds.
According to Life Sciences Review,"Psycheceutical's combination of innovative technologies and neurological experience helps to differentiate them in the bioscience market. Targeted drug delivery to the brain can both enhance compound efficacy and mitigate side effects. Psycheceutical achieves this with two patented technologies, theNeuroDirect™ topical delivery systemandJanus particles. Psycheceutical's focus on delivery technology upholds enormous potential."
"We are proud to receive this distinction from Life Sciences Review and are honored to join the list of so many exciting biotech startups," said Psycheceutical CEO Chad Harman. "This type of award drives us to move as rapidly as possible into clinical phase testing and development so that more people can access the profound benefits of psychedelic medicine, with non-intimidating and cost-effective treatment options."
The company's novel NeuroDirect™ ketamine topical cream to treat PTSD has already shown positive pre-clinical results. Data from a recently published study in Drug Development and Delivery Journal supports the potential of NeuroDirect ketamine topical cream as an improved treatment for PTSD. In the study of 100 patients who didn't respond to traditional therapies, more than 80% trying NeuroDirect ketamine topical found it effective at treating their PTSD symptoms. "Discernible improvement[s] in anxiety, depression, paranoia and unrealistic fear, focusing issues, cloudy thinking, neuropathic pain, and other such symptoms were noted within 8-10 mi nutes of topical drug application. No psychogenic effects, such as hallucinations or dissociative phenomena, were experienced by any patient. To the contrary, patients indicated their thought processes were clearer, more focused, and that they were more keenly aware of surroundings."
Psycheceutical's unique delivery method for psychedelic compounds has caught the attention of industry trailblazers like Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). "I've been working in psychedelics for more than 40 years, and it's rare for me to come across something unique like the NeuroDirect topical cream that is currently being developed by Psycheceutical with the goal of delivering a psychedelic compound without a psychedelic experience or negative side effects," noted Doblin." Psycheceutical recently announced plans tobegin clinical trials in Q2 in Australia for its NeuroDirect ketamine topical cream as a treatment for PTSD. "I'm curious to learn about the results of Psycheceutical's upcoming clinical trials in Australia and to further evaluate this potential treatment. I look forward to reviewing more research data," said Doblin. "Sometimes the biggest breakthroughs are right under our noses."
About Psycheceutical Bioscience, Inc.Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize it s precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more atPsycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, including the transferability to the US FDA of trial results from trials conducted outside of the US (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact: Kaia Roman, VP, Strategy & Communications kaia.roman@psycheceutical.com
NEWS: Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
PR Newswire
10:00 AM ET
As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect™ketamine topical to treat PTSD, the company is named to Life Science Review's yearly Top Biotech Start-Up List
Psycheceutical Bioscience, Inc("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review'sTop 10 Biotech Startups for 2023. Psycheceutical earned recognition for its significant progress in developing innovative patented delivery technologies that are intended to increase the safety and efficacy of psychedelic compounds.
According to Life Sciences Review,"Psycheceutical's combination of innovative technologies and neurological experience helps to differentiate them in the bioscience market. Targeted drug delivery to the brain can both enhance compound efficacy and mitigate side effects. Psycheceutical achieves this with two patented technologies, theNeuroDirect™ topical delivery systemandJanus particles. Psycheceutical's focus on delivery technology upholds enormous potential."
"We are proud to receive this distinction from Life Sciences Review and are honored to join the list of so many exciting biotech startups," said Psycheceutical CEO Chad Harman. "This type of award drives us to move as rapidly as possible into clinical phase testing and development so that more people can access the profound benefits of psychedelic medicine, with non-intimidating and cost-effective treatment options."
The company's novel NeuroDirect™ ketamine topical cream to treat PTSD has already shown positive pre-clinical results. Data from a recently published study in Drug Development and Delivery Journal supports the potential of NeuroDirect ketamine topical cream as an improved treatment for PTSD. In the study of 100 patients who didn't respond to traditional therapies, more than 80% trying NeuroDirect ketamine topical found it effective at treating their PTSD symptoms. "Discernible improvement[s] in anxiety, depression, paranoia and unrealistic fear, focusing issues, cloudy thinking, neuropathic pain, and other such symptoms were noted within 8-10 mi nutes of topical drug application. No psychogenic effects, such as hallucinations or dissociative phenomena, were experienced by any patient. To the contrary, patients indicated their thought processes were clearer, more focused, and that they were more keenly aware of surroundings."
Psycheceutical's unique delivery method for psychedelic compounds has caught the attention of industry trailblazers like Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). "I've been working in psychedelics for more than 40 years, and it's rare for me to come across something unique like the NeuroDirect topical cream that is currently being developed by Psycheceutical with the goal of delivering a psychedelic compound without a psychedelic experience or negative side effects," noted Doblin." Psycheceutical recently announced plans tobegin clinical trials in Q2 in Australia for its NeuroDirect ketamine topical cream as a treatment for PTSD. "I'm curious to learn about the results of Psycheceutical's upcoming clinical trials in Australia and to further evaluate this potential treatment. I look forward to reviewing more research data," said Doblin. "Sometimes the biggest breakthroughs are right under our noses."
About Psycheceutical Bioscience, Inc.Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize it s precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more atPsycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, including the transferability to the US FDA of trial results from trials conducted outside of the US (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact: Kaia Roman, VP, Strategy & Communications kaia.roman@psycheceutical.com
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
ya lol.dishes this week..never live it down..swamped out blaney for aric and then bamma oh well thats racing..always next week...
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
congrats all that burton wreck with 10 to go really changed the outcome for sho thats racing ya never know..
Sonasoft Corp. Announces Voluntary Delisting
GlobeNewswire
8:30 AM ET
Sonasoft Corp. Announces Voluntary DelistingGlobeNewswireMarch 13, 2023SAN JOSE, CA, March 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Today, Sonasoft Corp., a California Corporation, (OTCQB: SSFT) ("Sonasoft" or the "Company") announces that, after notifying FINRA and the OTC Markets Group, the Company voluntarily delisted from the OTC Markets Group OTCQB market, effective immediately.
The Company advises its shareholders that its common stock will no longer trade on the OTCQB market, but may be quoted on the OTC Pink market, also operated by OTC Markets Group. The Company can provide no assurances that any broker-dealer will continue to make a market in its common stock or that trading levels, liquidity, or quotation prices will be maintained. The Company also caution s its shareholders that trading on the OTC Pink market may be subject to limited availability of information, reduced transparency, and greater volatility.
CEO and Board Chairman Mike Khanna stated, "After careful contemplation, our Board originally pursued this path with the firm belief that doing so is in the best interests of our shareholders. This conviction has not changed. We are excited about our prospects for future growth as we now continue operations as a private entity."
About Sonasoft Corp. (OTCQB: SSFT)
Sonasoft was founded in Silicon Valley in 2003. For more information about the company, please visit: https://www.sonasoft.com. Sonasoft specializes in building end-to-end AI applications supported by the SAIBRE AI ecosystem.
For investor-specific information, please visit: https://www.sonasoft.com/investors/
Investor Relations Contact Josh Rose, Chief of Staff, Sonasoft Corporation. Phone: (408) 708-4000 jrose@sonasoft.com
Mornin All~~!!